Company:  ROCKWELL MEDICAL, INC. (RMTI)
Form Type:  10-Q
Filing Date:  5/7/2012 
CIK:  0001041024 
Address:  30142 S WIXOM RD 
City, State, Zip:  WIXOM, Michigan 48393 
Telephone:  (248) 960-9009 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$10.11  
Change: 
-0.22 (-2.13%)  
Trade Time: 
04:00 PM EST  
Market Cap: 
$412.20M
Description of Business
Rockwell Medical, Inc., incorporated in the state of Michigan in 1996, is a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron deficiency, secondary hyperparathyroidism and hemodialysis (also referred to as "dialysis"). Rockwell's lead investigational drug, Triferic�, also known as Soluble Ferric Pyrophosphate or SFP, delivers iron to the bone marrow in a non-invasive, physiologic manner to hemodialysis patients via dialysate during their regular dialysis treatment. We are preparing to submit a New Drug Application ("NDA") to the U.S. Food and Drug Administration ("FDA") in the first quarter of 2014 seeking marketing approval of Triferic�.
Register for EDGAR Pro and access this filing in:     
  FORM 10-Q
    PART I - FINANCIAL INFORMATION
      Item 1. Financial Statements
        BALANCE SHEET
        INCOME STATEMENT
        STOCKHOLDERS EQUITY
        CASH FLOW
        Notes to Consolidated Financial Statements
      Item 2. Management's Discussion and Analysis of Financial ...
      Item 3. Quantitative and Qualitative Disclosures about ...
      Item 4. Controls and Procedures
    PART II - OTHER INFORMATION
      Item 1A. Risk Factors
      Item 6. Exhibits
    SIGNATURES
    10-Q EXHIBIT INDEX
  EXHIBIT 31.1
    CERTIFICATION PURSUANT TO RULE 13a-14(a)
  EXHIBIT 31.2
    CERTIFICATION PURSUANT TO RULE 13a-14(a)
  EXHIBIT 32.1
    CERTIFICATION OF CHIEF EXECUTIVE OFFICER
BROKERAGE PARTNERS